JPS6253158B2 - - Google Patents

Info

Publication number
JPS6253158B2
JPS6253158B2 JP54121234A JP12123479A JPS6253158B2 JP S6253158 B2 JPS6253158 B2 JP S6253158B2 JP 54121234 A JP54121234 A JP 54121234A JP 12123479 A JP12123479 A JP 12123479A JP S6253158 B2 JPS6253158 B2 JP S6253158B2
Authority
JP
Japan
Prior art keywords
phm
ethyl acetate
15003phm
medium
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54121234A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5645483A (en
Inventor
Tooru Hasegawa
Mikio Izawa
Seiichi Tanida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP12123479A priority Critical patent/JPS5645483A/ja
Priority to EP80105161A priority patent/EP0026338A1/en
Priority to US06/188,242 priority patent/US4331598A/en
Priority to CA000360453A priority patent/CA1155073A/en
Publication of JPS5645483A publication Critical patent/JPS5645483A/ja
Priority to US06/347,724 priority patent/US4450234A/en
Publication of JPS6253158B2 publication Critical patent/JPS6253158B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/365—Nocardia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/872—Nocardia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP12123479A 1979-09-19 1979-09-19 C-15003phm and its preparation Granted JPS5645483A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP12123479A JPS5645483A (en) 1979-09-19 1979-09-19 C-15003phm and its preparation
EP80105161A EP0026338A1 (en) 1979-09-19 1980-08-29 Antibiotic C-15003 PHM, production thereof and microorganisms for its production
US06/188,242 US4331598A (en) 1979-09-19 1980-09-17 Maytansinoids
CA000360453A CA1155073A (en) 1979-09-19 1980-09-18 Antibiotic c-15003 phm and production thereof
US06/347,724 US4450234A (en) 1979-09-19 1982-02-10 Antibiotic C-15003 PHM and production thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12123479A JPS5645483A (en) 1979-09-19 1979-09-19 C-15003phm and its preparation

Publications (2)

Publication Number Publication Date
JPS5645483A JPS5645483A (en) 1981-04-25
JPS6253158B2 true JPS6253158B2 (OSRAM) 1987-11-09

Family

ID=14806225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP12123479A Granted JPS5645483A (en) 1979-09-19 1979-09-19 C-15003phm and its preparation

Country Status (4)

Country Link
US (2) US4331598A (OSRAM)
EP (1) EP0026338A1 (OSRAM)
JP (1) JPS5645483A (OSRAM)
CA (1) CA1155073A (OSRAM)

Families Citing this family (447)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW414040U (en) * 1997-09-10 2000-12-01 Takano Co Ltd Device for tilting, swaying and fastening
BR0012196A (pt) 1999-06-25 2002-03-19 Genentech Inc Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6573074B2 (en) * 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP2163256B1 (en) 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
KR100628425B1 (ko) * 2001-06-20 2006-09-28 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
JP2005536439A (ja) 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物と方法
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
NZ533933A (en) 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
US6790954B2 (en) * 2002-01-29 2004-09-14 Immunogen, Inc. Mutant Actinosynnema pretiosum strain with increased maytansinoid production
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
EP1633784B1 (en) 2003-05-09 2011-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2004240541B2 (en) 2003-05-20 2009-08-20 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
CN104059147A (zh) 2003-06-27 2014-09-24 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
AU2004259638C1 (en) 2003-07-08 2018-12-20 Novartis Pharma Ag IL-17 A/F heterologous polypeptides and therapeutic uses thereof
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
ATE453405T1 (de) 2003-11-17 2010-01-15 Genentech Inc Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
CN1922210A (zh) 2003-12-19 2007-02-28 健泰科生物技术公司 可用作治疗剂的单价抗体片段
BRPI0510883B8 (pt) * 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
WO2006014729A2 (en) 2004-07-20 2006-02-09 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
KR101222254B1 (ko) 2004-07-26 2013-01-16 제넨테크, 인크. 간세포 성장 인자 활성화를 조정하기 위한 조성물 및 방법
CA2486285C (en) * 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
EP1784426B1 (en) * 2004-09-03 2011-11-23 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
DK1841793T3 (da) 2005-01-07 2010-07-19 Diadexus Inc Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
JP2009504183A (ja) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
IL282138B2 (en) 2005-08-24 2024-01-01 Immunogen Inc Process for preparing purified drug conjugates
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US20090293137A1 (en) 2005-11-21 2009-11-26 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
US8957187B2 (en) * 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
CN105859886A (zh) 2005-12-02 2016-08-17 健泰科生物技术公司 牵涉与il-22和il-22r结合的抗体的组合物和方法
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007067698A2 (en) * 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Isolation of ansamitocins
EP1973948B1 (en) 2005-12-15 2015-02-11 Genentech, Inc. Methods and compositions for targeting polyubiquitin
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
RU2450020C2 (ru) 2006-01-05 2012-05-10 Дженентек, Инк. АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ZA200806187B (en) 2006-01-20 2009-10-28 Genentech Inc Anti-EphrinB2 antibodies and methods using same
ZA200807714B (en) 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
EP2007428A2 (en) 2006-04-05 2008-12-31 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
JP2009536022A (ja) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
HRP20140172T1 (hr) 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
US20100008910A1 (en) 2006-09-12 2010-01-14 John Chant Methods and compositions for the diagnosis and treatment of cancer
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2667019C (en) 2006-10-27 2016-03-29 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
MX338185B (es) 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
PE20081760A1 (es) 2007-02-09 2009-01-01 Genentech Inc Anticuerpos anti-robo4 y sus usos
EP2134854B1 (en) 2007-03-15 2015-04-15 Ludwig Institute for Cancer Research Ltd. Treatment method using egfr antibodies and src inhibitors and related formulations
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP5779350B2 (ja) 2007-03-27 2015-09-16 シー レーン バイオテクノロジーズ， エルエルシー 抗体代替軽鎖配列を含む構築物およびライブラリー
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
EP2641618A3 (en) 2007-07-16 2013-10-23 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
CL2008002085A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
WO2009023265A1 (en) 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
HUE037489T2 (hu) * 2007-08-29 2018-08-28 Sanofi Sa Humanizált anti-CXCR5 antitestek, azok származékai és alkalmazásuk
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
AU2008321016B2 (en) 2007-11-12 2013-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
US9221914B2 (en) 2007-12-26 2015-12-29 Biotest Ag Agents targeting CD138 and uses thereof
EP2238169A1 (en) * 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
SI2242772T1 (sl) * 2007-12-26 2015-03-31 Biotest Ag Imunokonjugati, ki ciljajo v CD138, in njihova uporaba
BRPI0821417A2 (pt) * 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
US8133488B2 (en) 2008-01-18 2012-03-13 Genentech, Inc. Methods and compositions for targeting polyubiquitin
CN104650230A (zh) 2008-01-31 2015-05-27 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
WO2009114560A2 (en) 2008-03-10 2009-09-17 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of cytomegalovirus
MY166445A (en) 2008-03-18 2018-06-27 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use
EP3605088A1 (en) 2008-04-09 2020-02-05 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN104524590B (zh) 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
KR101361905B1 (ko) * 2008-05-16 2014-02-21 제넨테크, 인크. 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
AU2008361352B2 (en) 2008-09-07 2013-05-09 Glyconex Inc. Anti-extended Type I glycosphingolipid antibody, derivatives thereof and use
AR073717A1 (es) 2008-10-01 2010-11-24 Genentech Inc Anticuerpos anti-notch2 de murino y humano, y metodos de uso
KR20110101212A (ko) 2008-12-17 2011-09-15 제넨테크, 인크. Ｃ형 간염 바이러스 조합 요법
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
PE20120553A1 (es) 2009-03-25 2012-05-18 Genentech Inc Anticuerpos anti-fgfr3
EP2414399A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Anti-fcrh5 antibodies and immunoconjugates and methods of use
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
SG175305A1 (en) * 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
US8481694B2 (en) 2009-04-29 2013-07-09 Bio-Rad Laboratories, Inc. Purification of immunoconjugates
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
CA2762302A1 (en) 2009-05-20 2010-11-25 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
RS58810B1 (sr) 2009-06-03 2019-07-31 Immunogen Inc Metodi konjugacije
BRPI1013016A2 (pt) 2009-06-04 2016-03-29 Massachusetts Inst Technology "métodos para identificação de locais para conjugação de igg"
CN102802661B (zh) 2009-06-22 2016-01-13 米迪缪尼有限公司 用于位点特异性偶联的工程改造的Fc区
AU2010278844A1 (en) 2009-07-31 2012-02-09 Genentech, Inc. Inhibition of tumor metastasis using Bv8- or G-CSF-antagonists
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
EP2491058A1 (en) 2009-10-19 2012-08-29 F. Hoffmann-La Roche AG Modulators of hepatocyte growth factor activator
KR20120105447A (ko) 2009-10-22 2012-09-25 제넨테크, 인크. 항-헵신 항체 및 그의 사용 방법
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
MX2012005168A (es) 2009-11-05 2012-06-08 Genentech Inc Metodos y composicion para secrecion de polipeptidos heterologos.
RU2015132142A (ru) 2009-11-30 2015-12-20 Дженентек, Инк. Композиции и способы для диагностики и лечения опухоли
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
US8486397B2 (en) 2009-12-11 2013-07-16 Genentech, Inc. Anti-VEGF-C antibodies and methods using same
US8771685B2 (en) 2009-12-23 2014-07-08 F. Hoffmann-La Roche Ag Anti-BV8 antibodies and uses thereof
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
KR20130004579A (ko) 2010-02-23 2013-01-11 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
KR20230044026A (ko) 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
CN106046159B (zh) 2010-03-12 2020-06-16 德彪发姆国际有限公司 Cd37结合分子及其免疫缀合物
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
MA34291B1 (fr) 2010-05-03 2013-06-01 Genentech Inc Compositions et méthodes de diagnostic et de traitement d'une tumeur
CN103119442A (zh) 2010-06-03 2013-05-22 霍夫曼-拉罗奇有限公司 抗体和免疫偶联物的免疫peg成像及其用途
WO2011156328A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP3029066B1 (en) 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
EP2603237A4 (en) 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
PL3556396T3 (pl) 2010-08-31 2022-09-12 Theraclone Sciences, Inc. Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
CN103328511B (zh) 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
IL319612A (en) 2010-09-29 2025-05-01 Seagen Inc Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
DK2625197T3 (en) 2010-10-05 2016-10-03 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
WO2012058592A2 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Non-antagonistic egfr-binding molecules and immunoconjugates thereof
CA2815277A1 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
CN103269712B (zh) * 2010-11-03 2016-09-21 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
US8916160B2 (en) 2011-02-14 2014-12-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
RU2013144392A (ru) 2011-03-03 2015-04-10 Апексиджен, Инк. Антитела к рецептору il-6 и способы применения
KR20140012131A (ko) 2011-03-15 2014-01-29 테라클론 사이언시스, 아이엔씨. 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
TWI700093B (zh) 2011-03-16 2020-08-01 法商賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
SMT201900114T1 (it) 2011-03-29 2019-02-28 Immunogen Inc Preparazione di coniugati maytansinoide-anticorpo mediante un processo a fase unica
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
CN106928362B (zh) 2011-04-29 2021-10-26 埃派斯进有限公司 抗-cd40抗体及其使用方法
CA2835203A1 (en) 2011-05-09 2012-11-15 University Of Virginia Patent Foundation Compositions and methods for treating cancer
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
EP2717916B1 (en) 2011-06-10 2017-03-08 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EA029797B1 (ru) 2011-06-21 2018-05-31 Иммуноджен, Инк. Новые производные майтанзиноида с пептидным линкером и их конъюгаты
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
RU2014109985A (ru) 2011-08-17 2015-09-27 Дженентек, Инк. Ингибирование ангиогенеза в рефрактерных опухолях
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
BR112014006822B1 (pt) 2011-09-22 2021-05-18 Amgen Inc. Proteína de ligação ao antígeno cd27l, composição compreendendo uma proteína de ligação ao antígeno cd27l, ácido nucleico isolado, vetor de expressão, célula hospedeira recombinante procariótica, método de preparação de um conjugado de droga e anticorpo cd27l e uso de uma proteína de ligação ao antígeno cd27l
CA3182462A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP2776051A4 (en) 2011-10-28 2015-06-17 Hoffmann La Roche THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
CA2854153A1 (en) 2011-11-02 2013-05-10 Apexigen, Inc. Anti-kdr antibodies and methods of use
CN104168922A (zh) 2011-11-16 2014-11-26 安姆根有限公司 治疗表皮生长因子缺失突变体viii相关疾病的方法
MX2014006087A (es) 2011-11-21 2014-08-01 Immunogen Inc Metodo de tratamiento de tumores que son resistentes a terapias contra el receptor del factor de crecimiento epidermico (egfr) con agentes citotoxicos conjugados con anticuerpos dirigidos contra el receptor del factor de crecimiento epidermico.
US10117932B2 (en) 2011-12-08 2018-11-06 Biotest Ag Uses of immunoconjugates targeting CD138
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
US20150011736A1 (en) 2012-01-20 2015-01-08 Sea Lane Biotechnologies, Llc Binding molecule conjugates
JP6486686B2 (ja) 2012-02-10 2019-03-20 ジェネンテック， インコーポレイテッド 単鎖抗体及び他のヘテロ多量体
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CN104379602B (zh) 2012-03-08 2017-05-03 哈洛齐梅公司 具有条件活性的抗表皮生长因子受体抗体及其使用方法
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9056910B2 (en) 2012-05-01 2015-06-16 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
CN102731526B (zh) * 2012-05-14 2014-09-10 福建省微生物研究所 安丝菌素类化合物及其制备方法
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
CN102732581B (zh) * 2012-07-18 2014-07-16 上海交联药物研发有限公司 一种高表达安丝菌素p-3的方法
JP6302909B2 (ja) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ シアリダーゼの同定および画像化のための細胞透過性プローブ
KR102355959B1 (ko) 2012-08-23 2022-01-27 어젠시스 인코포레이티드 158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
DK2900676T3 (en) 2012-09-26 2019-04-08 Immunogen Inc IMPROVED PROCEDURES FOR ACYLATION OF MAYTANSINOL
NZ707091A (en) 2012-10-04 2018-12-21 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
KR20240063172A (ko) 2012-11-20 2024-05-09 사노피 항-ceacam5 항체 및 이의 용도
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
ES2871816T3 (es) 2012-12-27 2021-11-02 Sanofi Sa Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
WO2014159835A1 (en) 2013-03-14 2014-10-02 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
JP6594855B2 (ja) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
EA035253B1 (ru) 2013-03-15 2020-05-21 Новартис Аг Лекарственные конъюгаты антител
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
MY199321A (en) 2013-05-30 2023-10-24 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN111518199A (zh) 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
EP3747465A1 (en) 2013-07-31 2020-12-09 BioNTech AG Diagnosis and therapy of cancer involving cancer stem cells
CN105722534B (zh) 2013-08-01 2019-05-31 艾更斯司股份有限公司 结合cd37蛋白的抗体药物偶联物(adc)
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
HK1226081A1 (zh) 2013-09-12 2017-09-22 Halozyme, Inc. 修饰的抗表皮生长因子受体抗体及其使用方法
AR097685A1 (es) 2013-09-17 2016-04-06 Genentech Inc Métodos de uso de anticuerpos anti-lgr5
WO2015054400A2 (en) 2013-10-08 2015-04-16 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
WO2015054669A1 (en) 2013-10-11 2015-04-16 Asana Biosciences, Llc Protein-polymer-drug conjugates
CN105745224B (zh) 2013-10-11 2019-11-05 牛津生物疗法有限公司 用于治疗癌症的针对ly75的偶联抗体
CN105813654B (zh) 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) Tem8抗体及其用途
EA032231B1 (ru) 2013-10-11 2019-04-30 Мерсана Терапьютикс, Инк. Конъюгаты белок-полимер-лекарственное средство
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
JP2016538283A (ja) 2013-11-13 2016-12-08 ザイムワークス，インコーポレイテッド Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
AU2014362238A1 (en) 2013-12-13 2016-06-09 Genentech, Inc. Anti-CD33 antibodies and immunoconjugates
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2017507118A (ja) 2014-01-16 2017-03-16 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんの処置および検出のための組成物および方法
EP3096797A1 (en) 2014-01-24 2016-11-30 F. Hoffmann-La Roche AG Methods of using anti-steap1 antibodies and immunoconjugates
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
PT3122757T (pt) 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Ligantes carregados e as suas utilizações em conjugação
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
MX385936B (es) 2014-03-28 2025-03-11 Xencor Inc Anticuerpos biespecíficos que se unen a cd38 y cd3.
HK1232127A1 (zh) 2014-04-11 2018-01-05 Medimmune, Llc 双特异性her2抗体
KR20230164192A (ko) 2014-05-06 2023-12-01 제넨테크, 인크. 포유동물 세포를 사용한 이종다량체 단백질의 생산
BR112016027222A2 (pt) 2014-05-22 2018-01-30 Genentech Inc anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
TWI717319B (zh) 2014-05-27 2021-02-01 中央研究院 得自類桿菌屬之岩藻糖苷酶及其用途
US20150344585A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
TWI679020B (zh) 2014-05-27 2019-12-11 中央研究院 抗ｈｅｒ２醣抗體及其用途
TWI732738B (zh) 2014-05-28 2021-07-11 中央研究院 抗TNF-α醣抗體及其用途
EP3194449A1 (en) 2014-07-24 2017-07-26 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
MA40513A (fr) 2014-08-12 2017-06-21 Novartis Ag Conjugués médicament-anticorps anti-cdh6
ES3034398T3 (en) 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
US20160058884A1 (en) 2014-09-02 2016-03-03 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
WO2016040724A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
PE20170935A1 (es) 2014-09-12 2017-07-13 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
CR20170095A (es) 2014-09-12 2017-07-19 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados referencias recíprocas con solicitudes relacionadas
EP3262071B8 (en) 2014-09-23 2022-05-18 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
CA2962783A1 (en) 2014-10-01 2016-04-07 Medimmune, Llc Method of conjugating a polypeptide
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
MA40934A (fr) 2014-11-19 2017-09-27 Immunogen Inc Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
HRP20211273T1 (hr) 2014-11-26 2021-11-12 Xencor, Inc. Heterodimerna protutijela koja vežu cd3 i cd20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
MX2017006918A (es) 2014-11-26 2018-01-25 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38.
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
KR20170125799A (ko) 2014-12-04 2017-11-15 셀진 코포레이션 생체분자 컨쥬게이트
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
CN112430268A (zh) 2015-01-24 2021-03-02 中央研究院 癌症标记及其使用方法
EP3253784B1 (en) 2015-02-04 2020-05-06 Genentech, Inc. Mutant smoothened and methods of using the same
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10780179B2 (en) 2015-03-18 2020-09-22 Immunobiochem Corporation Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
EP3286227A2 (en) 2015-04-24 2018-02-28 F. Hoffmann-La Roche AG Multispecific antigen-binding proteins
CN108603170A (zh) 2015-06-12 2018-09-28 莱蒂恩技术公司 用工程改造的t细胞治疗癌症的方法
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
CN108449940B (zh) 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3349796A4 (en) 2015-09-17 2019-05-29 ImmunoGen, Inc. THERAPEUTIC COMBINATIONS WITH ANTI-FOLR1 IMMUNOCONJUGATES
CA2996205A1 (en) 2015-09-20 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
EP3660044A1 (en) 2015-10-09 2020-06-03 Miltenyi Biotec Technology, Inc. Chimeric antigen receptors and methods of use
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
BR112018015259A2 (pt) 2016-01-27 2018-12-18 Medimmune Llc métodos para preparação de anticorpos com um padrão de glicosilação definido
EP3411077A1 (en) 2016-02-05 2018-12-12 ImmunoGen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
TW201808978A (zh) 2016-03-08 2018-03-16 中央研究院 N-聚醣及其陣列之模組化合成方法
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CA3056374A1 (en) 2016-04-13 2017-10-19 Orimabs Ltd. Anti-psma antibodies and use thereof
SG11201808994YA (en) 2016-04-15 2018-11-29 Bioatla Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
ES2930255T3 (es) 2016-05-13 2022-12-09 Bioatla Inc Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
FI3468586T3 (fi) 2016-06-14 2024-10-29 Xencor Inc Bispesifisiä immuuniaktivaatiota vapauttavia vasta-aineita
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
EP3475304B1 (en) 2016-06-28 2022-03-23 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US11066479B2 (en) 2016-08-02 2021-07-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11453712B2 (en) 2016-09-02 2022-09-27 Lentigen Technology Inc. Compositions and methods for treating cancer with DuoCARs
CA3040504A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. Il15/il15ra heterodimeric fc-fusion proteins
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
CN110099682B (zh) 2016-11-14 2023-03-31 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
WO2018091724A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EP3559038B1 (en) 2016-12-21 2022-12-14 The United States of America as represented by The Secretary Department of Health and Human Services Human monoclonal antibodies specific for flt3 and uses thereof
EP3882265B1 (en) 2017-01-09 2022-11-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
CN110997719B (zh) 2017-03-24 2020-12-11 莱蒂恩技术公司 用于用抗cd33免疫疗法治疗癌症的组合物和方法
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
US11389480B2 (en) 2017-05-19 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
JP7320458B2 (ja) 2017-06-22 2023-08-03 メルサナ セラピューティクス インコーポレイテッド 薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
CA3066953A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
WO2019028051A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
ES3025461T3 (en) 2017-08-22 2025-06-09 Purdue Research Foundation Fbsa-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers
US10501539B2 (en) 2017-09-15 2019-12-10 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
NZ762376A (en) 2017-09-19 2022-08-26 Scherrer Inst Paul Transglutaminase conjugation method and linker
EP4279584A3 (en) 2017-10-16 2024-03-06 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd22 immunotherapy
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
WO2019090110A1 (en) 2017-11-03 2019-05-09 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-ror1 immunotherapy
WO2019094637A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
IL316155A (en) 2017-11-29 2024-12-01 Heidelberg Pharma Res Compositions and Methods for the Depletion of CD5(PLUS) CELLS
JP2021506260A (ja) 2017-12-15 2021-02-22 ジュノー セラピューティクス インコーポレイテッド 抗ｃｃｔ５結合分子およびその使用方法
KR102722731B1 (ko) 2017-12-19 2024-10-25 젠코어 인코포레이티드 조작된 il-2 fc 융합 단백질
CN111954677A (zh) 2017-12-20 2020-11-17 莱蒂恩技术公司 用于用免疫治疗来治疗hiv/aids的组合物和方法
AU2019240403A1 (en) 2018-03-23 2020-10-08 Seagen Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
JP2021521784A (ja) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
EP3787691A1 (en) 2018-05-04 2021-03-10 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
ES2975330T3 (es) 2018-05-04 2024-07-04 Tagworks Pharmaceuticals B V Compuestos que comprenden un enlazador para aumentar la estabilidad del trans-cicloocteno
MX2020012755A (es) 2018-05-30 2021-02-26 Debiopharm Int Sa Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37).
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
PE20211091A1 (es) 2018-07-02 2021-06-14 Amgen Inc Proteina de union al antigeno anti-steap1
EP3820903A1 (en) 2018-07-12 2021-05-19 The United States of America, as represented by the Secretary, Department of Health and Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
AU2019311077B2 (en) 2018-07-23 2025-05-29 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
CA3106544A1 (en) 2018-08-08 2020-02-13 Mitchell Ho High affinity monoclonal antibodies targeting glypican-2 and uses thereof
JP7546553B2 (ja) 2018-09-20 2024-09-06 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ１２３免疫療法によりがんを処置するための組成物および方法
CA3114349A1 (en) 2018-09-26 2020-04-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
EP3873534A1 (en) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
JP7583720B2 (ja) 2018-11-30 2024-11-14 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ３８免疫療法によりがんを処置するための組成物および方法
KR20210100668A (ko) 2018-12-06 2021-08-17 제넨테크, 인크. 항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
EP3883608A1 (en) 2019-01-08 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
US12122843B2 (en) 2019-01-22 2024-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
BR112021014636A2 (pt) 2019-02-07 2021-12-21 Sanofi Sa Uso de imunoconjugados anti-ceacam5 para tratamento de câncer de pulmão
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
MX2021010390A (es) 2019-03-01 2021-11-17 Xencor Inc Anticuerpos heterodimericos que se unen a enpp3 y cd3.
US11969443B2 (en) 2019-03-06 2024-04-30 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
JP7629902B2 (ja) 2019-03-19 2025-02-14 パウル・シェラー・インスティトゥート グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法
EP3968993A1 (en) 2019-05-14 2022-03-23 F. Hoffmann-La Roche AG Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
US11052112B2 (en) 2019-05-30 2021-07-06 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-BCMA immunotherapy
CA3143925A1 (en) 2019-06-17 2020-12-24 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
KR20220031054A (ko) 2019-07-02 2022-03-11 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Egfrviii에 결합하는 단일클론 항체 및 이의 용도
US20220267452A1 (en) 2019-07-12 2022-08-25 Chugai Seiyaku Kabushiki Kaisha Anti-mutation type fgfr3 antibody and use therefor
CR20220166A (es) 2019-10-18 2022-06-15 Genentech Inc Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes
EP4031250A1 (en) 2019-10-22 2022-07-27 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
WO2021118968A1 (en) 2019-12-12 2021-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for cd276 and uses thereof
CN115427083A (zh) 2020-04-24 2022-12-02 赛诺菲 含有抗ceacam5抗体缀合物和西妥昔单抗的抗肿瘤组合
CA3181000A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
BR112022021441A2 (pt) 2020-04-24 2022-12-13 Genentech Inc Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
WO2021214222A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
AU2021260823A1 (en) 2020-04-24 2023-01-05 Sanofi Antitumor combinations containing anti-CEACAM5 antibody conjugates and FOLFOX
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3171101A1 (en) 2020-06-22 2021-12-30 Dina SCHNEIDER Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
CN116406302A (zh) 2020-09-18 2023-07-07 阿拉里斯生物技术股份公司 用基于氨基酸的接头的谷氨酰胺转胺酶缀合方法
AU2021366341A1 (en) 2020-10-25 2023-06-22 Araris Biotech Ag Means and methods for producing antibody-linker conjugates
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CN116801898A (zh) 2020-11-05 2023-09-22 莱蒂恩技术公司 用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
EP4240415A1 (en) 2020-11-08 2023-09-13 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
CN117157319A (zh) 2021-03-09 2023-12-01 Xencor股份有限公司 结合cd3和cldn6的异二聚抗体
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Ｃｄ７０結合劑、其結合物及其使用方法
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
AU2022273063A1 (en) 2021-05-12 2023-11-23 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
JP2024521187A (ja) 2021-05-28 2024-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ガンの治療のための組み合わせ療法
WO2022261017A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
US20250327057A1 (en) 2021-09-06 2025-10-23 Veraxa Biotech Gmbh Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
EP4412713A1 (en) 2021-10-05 2024-08-14 GlaxoSmithKline Intellectual Property Development Ltd Combination therapies for treating cancer
JP2024539989A (ja) 2021-10-25 2024-10-31 アラリス バイオテック アーゲー 抗体－リンカーコンジュゲートを生成する方法
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
MX2024005484A (es) 2021-11-05 2024-07-19 Sanofi Sa Combinaciones antineoplásicas que contienen conjugados de anticuerpo-fármaco anti-ceacam5 y anticuerpos anti-vegfr-2.
WO2023089314A1 (en) 2021-11-18 2023-05-25 Oxford Biotherapeutics Limited Pharmaceutical combinations
WO2023092099A1 (en) 2021-11-19 2023-05-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
DK4186529T3 (da) 2021-11-25 2025-08-25 Veraxa Biotech Gmbh Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
CA3238627A1 (en) 2021-11-25 2023-06-01 Christine Kohler Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
KR20240112922A (ko) 2021-12-02 2024-07-19 사노피 Ceacam5 adc - 항-pd1/pd-l1 병용 요법
MX2024006766A (es) 2021-12-02 2024-07-29 Sanofi Sa Prueba de cea para la selección de pacientes en tratamiento del cáncer.
US20250135011A1 (en) 2021-12-08 2025-05-01 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
EP4314031B1 (en) 2022-02-15 2024-03-13 Tagworks Pharmaceuticals B.V. Masked il12 protein
CN118742328A (zh) 2022-02-22 2024-10-01 阿拉里斯生物技术股份公司 包含两个或更多个有效载荷的肽接头
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
KR20250049569A (ko) 2022-07-15 2025-04-11 페온 테라퓨틱스 리미티드 항체-약물 접합체
CN119923410A (zh) 2022-07-28 2025-05-02 莱蒂恩技术公司 用于治疗实体瘤的嵌合抗原受体治疗
EP4577571A1 (en) 2022-08-26 2025-07-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
WO2024080872A1 (en) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Strained bicyclononenes
CN120569216A (zh) 2023-01-20 2025-08-29 巴斯夫欧洲公司 稳定型生物聚合物组合物、其制造和用途
KR20250154496A (ko) 2023-03-01 2025-10-28 사노피 Ceacam5를 발현하는 신경내분비암을 치료하기 위한 항-ceacam5 면역접합체의 용도
EP4427763A1 (en) 2023-03-06 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
AU2024237490A1 (en) 2023-03-10 2025-09-25 Tagworks Pharmaceuticals B.V. Trans-cyclooctene with improved t-linker
TW202500194A (zh) 2023-03-23 2025-01-01 法商賽諾菲公司 用於癌症治療中患者選擇之ＣＥＡＣＡＭ５ ｍＲＮＡ分析
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
TW202513094A (zh) 2023-06-05 2025-04-01 法商賽諾菲公司 含有抗ceacam5抗體藥物接合物、抗pd1/pd-l1抗體及抗ctla4抗體之抗腫瘤組合
WO2024254455A1 (en) 2023-06-08 2024-12-12 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025021929A1 (en) 2023-07-27 2025-01-30 Veraxa Biotech Gmbh Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
WO2025056807A1 (en) 2023-09-15 2025-03-20 Basf Se Stabilized biopolymer composition, their manufacture and use
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025169012A1 (en) 2024-02-06 2025-08-14 Sanofi Methods of treating ceacam5-expressing cancers
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
WO2025174248A1 (en) 2024-02-16 2025-08-21 Tagworks Pharmaceuticals B.V. Trans-cyclooctenes with "or gate" release
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162940A (en) * 1977-03-31 1979-07-31 Takeda Chemical Industries, Ltd. Method for producing Antibiotic C-15003 by culturing nocardia
PH13381A (en) * 1977-03-31 1980-03-25 Takeda Chemical Industries Ltd Antibiotic c-15003
US4151042A (en) * 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
JPS5948992B2 (ja) * 1977-08-04 1984-11-30 武田薬品工業株式会社 抗生物質ｃ−１４４８２ａ↓１
US4137230A (en) * 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
JPS6010720B2 (ja) * 1977-11-18 1985-03-19 武田薬品工業株式会社 抗生物質ｃ―１５００３ ｐ―４の製造法
JPS6016236B2 (ja) * 1977-11-18 1985-04-24 武田薬品工業株式会社 抗生物質ｃ―１５００３ ｐ―３の製造法
JPS55104297A (en) * 1979-02-02 1980-08-09 Takeda Chem Ind Ltd Antibiotic substance c-14482 b1, b2 and b3

Also Published As

Publication number Publication date
JPS5645483A (en) 1981-04-25
CA1155073A (en) 1983-10-11
US4331598A (en) 1982-05-25
EP0026338A1 (en) 1981-04-08
US4450234A (en) 1984-05-22

Similar Documents

Publication Publication Date Title
JPS6253158B2 (OSRAM)
US4151042A (en) Method for producing maytansinol and its derivatives
US4225494A (en) Maytansinol esters
US4362663A (en) Maytansinoid compound
US4322348A (en) Maytansinoids
EP0031430B1 (en) A method for the production of antibiotic c-15003 p-3
US4228239A (en) Method for producing antibiotic C-15003 P-3
KR920001366B1 (ko) 새로운 항암 항생복합체 bbm-1675의 제조방법
DK143570B (da) Fremgangsmaade til fremstilling af maytansinol maytanacin og eller maytansinolpropionat
US4229533A (en) Method for producing antibiotic C-15003 P-4
US4292309A (en) Antibiotics C-14482 B1, B2 and B3
US4595770A (en) Antibiotic compound and process for recovery thereof from a fermentation broth
US4335108A (en) Paulomycin A and B and preparation thereof
CA1107212A (en) Antibiotic c-15003
JPS5948992B2 (ja) 抗生物質ｃ−１４４８２ａ↓１
US4835141A (en) Neutral macrolide antibiotics from Streptomyces
US4306021A (en) Composition of matter and process
KR810001056B1 (ko) 항생물질 c-15003의 제조법
JPS6034556B2 (ja) 抗生物質ｃ−１５００３
US4956283A (en) Process for preparing macrolide antibiotics by culturing streptomyces hirsutus ATCC 53513
KR820001433B1 (ko) 항생물질 c-15003 p-4의 제조법
KR820001204B1 (ko) 항생물질 c-15003 p-3의 제조법
US4331659A (en) Antibiotic U-62,162 and process of making
KR810000510B1 (ko) 메이탄시노올 유도체의 제조방법
CA1121814A (en) Antibiotic c-15003